NCT07442669

Utilization of Lung Ultrasound Score in Decision for Minimally Invasive Surfactant Administration

Not yet recruiting NA Last updated 2 March 2026

What this trial tests

NA trial testing Lung ultrasound in Respiratory Distress Syndrome, Newborn in 100 participants. Not yet recruiting.

Timeline

1 March 2026

Primary endpoint
28 February 2028

5 March 2028

Quick facts

Lead sponsor	Hackensack Meridian Health
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 March 2026
Primary completion	28 February 2028
Estimated completion	5 March 2028
Sites	1 location across United States

Drugs / interventions tested

• Lung ultrasound

Conditions studied

• Respiratory Distress Syndrome, Newborn — all drugs for Respiratory Distress Syndrome, Newborn →
• Respiratory Distress Syndrome in Premature Infant — all drugs for Respiratory Distress Syndrome in Premature Infant →

Sponsor

Hackensack Meridian Health — full company profile →

Who can join

Adults 27 Weeks to 34 Weeks, any sex, with Respiratory Distress Syndrome, Newborn or Respiratory Distress Syndrome in Premature Infant. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective randomized controlled study aims to determine if using a lung ultrasound score can lead to a faster diagnosis of severe respiratory distress syndrome and quicker administration of surfactant in moderately and late-preterm infants. The research will involve 100 infants, with 67 in the prospective group and 33 serving as controls.

The primary goal is to shorten the time to treatment for these vulnerable newborns. The study will also assess whether this ultrasound-guided approach improves short-term respiratory outcomes. These secondary objectives include measuring any decrease in the need for and duration of mechanical ventilation, the length of non-invasive respiratory support, and the overall need for oxygen.

The study population includes infants born between 27 and 34 6/7 weeks of gestation who are admitted to the NICU. Each participant will be monitored from birth until they are discharged or transferred. This research aligns with a growing body of evidence suggesting that lung ultrasound can be a valuable tool in neonatal care, potentially leading to earlier and more precise treatment for respiratory distress syndrome.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.